NPS Pharmaceuticals says on track for Natpara submission in mid-2013

The company said “We also continue to make strong progress towards completing our Biologic License Application for Natpara as the first replacement therapy for hypoparathyroidism. We remain on track to deliver a submission in line with our mid-2013 guidance...NPS continues to expect to end the year with at least $92M of cash and investments."

View Comments (0)